VX-880

Phase 3Biologic

Vertex Pharmaceuticals

VX-880 is one of 62 biologic programs targeting Type 1 Diabetes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 DiabetesActive, not recruiting

Diabetes Mellitus, Type 1Recruiting

Type 1 Diabetes MellitusActive, not recruiting

Type 1 DiabetesPhase 3

Active, not recruiting

Diabetes Mellitus, Type 1Phase 3

Recruiting

Type 1 Diabetes MellitusPhase 1

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

VX-880

Vertex Pharmaceuticals

Phase 3

1 2

Symlin

AstraZeneca

Preclinical

4 3

Symlin

AstraZeneca

Preclinical

3 4

Aldomet

Neurocrine Biosciences

Preclinical

2 5

Pitocin

RRetrophin

Preclinical

1 6

Glargine

Eli Lilly

Preclinical

4 7

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Foradil

Viatris

Preclinical

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 3Recruiting

Diabetes Mellitus, Type 1

NCT04786262

Clinical

Trials by Indication[1]

Diabetes Mellitus, Type 11 trial

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 3·NCT04786262·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VX-880. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VX-880 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VX-880. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Vertex Pharmaceuticals

VX-880

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Diabetes Mellitus, Type 11 trial

References

Drug Info

Quick Facts

Related News